Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201127
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Barrios, Vivencio | - |
dc.contributor.author | Pintó Sala, Xavier | - |
dc.contributor.author | Escobar, Carlos | - |
dc.contributor.author | Varona, José F. | - |
dc.contributor.author | Gámez, José M. | - |
dc.date.accessioned | 2023-07-25T10:26:01Z | - |
dc.date.available | 2023-07-25T10:26:01Z | - |
dc.date.issued | 2023-04-28 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | http://hdl.handle.net/2445/201127 | - |
dc.description.abstract | Despite steady improvements in cardiovascular disease (CVD) prevention, a scarce proportion of patients achieve the recommended LDL-C goals, even under high-intensity lipid-lowering therapy (LLT). Our study aimed to evaluate the attainment rate of LDL-C targets recommended by the 2019 European guidelines, and to characterize potential factors associated with LDL-C goal achievement and change patterns in LLT. We conducted a retrospective, observational study on patients treated with high-intensity atorvastatin or rosuvastatin +/- ezetimibe at cardiology and internal medicine clinics across Spain. It included 1570 evaluable patients (median age: 62 years; established CVD: 77.5% [myocardial infarction: 34.3%]; and 85.8% at very high cardiovascular risk). Rosuvastatin +/- ezetimibe was the LLT in 52.2% of patients, and atorvastatin +/- ezetimibe in 47.8%. LLT had been modified in 36.8% of patients (side effects: 10%), being the most common switch from atorvastatin- to rosuvastatin-based treatment (77.2%). The risk-based LDL-C goal attainment rate was 31.1%, with 78.2% high-risk and 71.7% very high-risk patients not achieving the recommended LDL-C targets. Established CVD and familial hypercholesterolemia were significantly associated with the non-achievement of LDL-C goals. Although having limitations, this study shows that the guideline-recommended LDL-C goal attainment rate is still suboptimal despite using high-intensity statin therapy in a real-world setting in Spain. | - |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/jcm12093187 | - |
dc.relation.ispartof | Journal of Clinical Medicine, 2023, vol. 12, num. 9 | - |
dc.relation.uri | https://doi.org/10.3390/jcm12093187 | - |
dc.rights | cc by (c) Barrios, Vivencio et al, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Colesterol | - |
dc.subject.classification | Malalties cardiovasculars | - |
dc.subject.other | Cholesterol | - |
dc.subject.other | Cardiovascular diseases | - |
dc.title | Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-07-03T10:33:38Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37176627 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-12-03187-v3.pdf | 1.47 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License